Clinical Trial

Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-11; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT06933277
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Multiple Myeloma
Enrollment 159 participants
Start Date 2025-08-29
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-10